Carl Zeiss: Recovery Has Started (OTCMKTS:CZMWY)
· seekingalpha.com
Carl Zeiss Meditec remains a Strong Buy despite prolonged challenges, with a revised price target of €65/share (ADR: $75.42). Read more on CZMWY stock here.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of CZMWY either through stock ownership, options, or other derivatives. I wrote this ...